| 摘要 |
The invention relates to novel formulations of anagrelide resulting in a non-immediate release of the active ingredient of anagrelide. The inventors have shown that pharmaceutical compositions comprising anagrelide particles, wherein at least 90% of said anagrelide particles are smaller than 10 μm, in combination with lactose monohydrate provide a formulation with reduced release characteristics when administered to a patient. Optionally, the pharmaceutical composition can further comprise povidone, crospovidone, microcristalline cellulose and/or magnesium stearate. |
